FDA approves Chemence Medical’s new Exofin precision pen
Chemence Medical has secured approval from the US Food and Drug Administration (FDA) for its Exofin precision pen for wound closure. The new medical device is part of
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More XChemence Medical has secured approval from the US Food and Drug Administration (FDA) for its Exofin precision pen for wound closure. The new medical device is part of
UK, med-tech company, Bedfont Scientific Ltd., is celebrating a brighter 2022 as the U.S. Food and Drug Administration (FDA) cleared its NObreath FeNO monitor for use in monitoring
SD Biosensor, Inc., a global in-vitro diagnostics company, is voluntarily recalling its STANDARD Q COVID-19 Ag Home Test in the United States, due to confirmed reports that the
Medical solutions company ConvaTec Group has agreed to acquire US-based medical device company Triad Life Sciences in a deal valued at around $450m. Based in Memphis of Tennessee,
Insulet has secured approval from the US Food and Drug Administration (FDA) for its Omnipod 5 automated insulin delivery system for individuals aged six years and older with
Kaman Composites – Vermont, Inc., an indirect, wholly owned subsidiary of Kaman Corporation (NYSE:KAMN), announces the expansion of its medical imaging program through the recent new partnership with
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC) to
InnovHeart has secured a $55m in series C financing to further develop its trans-septal Saturn transcatheter mitral valve replacement (TMVR) system. Led by Grand Pharmaceutical Group, the financing
Medical device company BioVentrix has acquired heart failure therapies developer MateraCor for an undisclosed sum. MateraCor, a Southern California based start-up, is engaged in the development of novel
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of the industry’s first full-service, at-home, 12-lead electrocardiogram (ECG) solution for use